EBITDA Margin % is calculated as EBITDA divided by its Revenue. PharmaEssentia's EBITDA for the
three
months ended in Dec. 2025 was NT$2,123 Mil. PharmaEssentia's Revenue for the
three
months ended in Dec. 2025 was NT$4,881 Mil. Therefore, PharmaEssentia's EBITDA margin for the quarter that ended in Dec. 2025 was 43.50%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PharmaEssentia EBITDA Margin % Related Terms
PharmaEssentia EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PharmaEssentia's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaEssentia's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaEssentia EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaEssentia's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PharmaEssentia's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaEssentia (TPE:6446) has a EBITDA Margin % of 43.50% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaEssentia and its competitors. According to the industry distribution chart, PharmaEssentia ranks #92 out of 956 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is PharmaEssentia's EBITDA Margin % too high?
PharmaEssentia's current EBITDA Margin % is 43.50%. The Drug Manufacturers industry median EBITDA Margin % is 12.52. PharmaEssentia's value of 43.50% is 247.6% above this industry median. Based on the distribution chart, PharmaEssentia ranks #92 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaEssentia has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PharmaEssentia's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaEssentia ranks #92 out of 956 companies for EBITDA Margin %. This places PharmaEssentia in the top 10% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. PharmaEssentia's value of 43.50% is 247.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaEssentia's current EBITDA Margin % of 43.50% is 247.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaEssentia and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaEssentia's current EBITDA Margin % is 43.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEssentia stock overvalued right now?
Based on GuruFocus' analysis, PharmaEssentia (TPE:6446) is currently considered Fairly Valued. The stock's GF Value™ is NT$1,350.18, compared to a current price of NT$1,445.00 — trading 7% above its estimated fair value. The current EBITDA Margin % is 43.50% and 247.6% above the Drug Manufacturers industry median of 12.52. PharmaEssentia's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PharmaEssentia (TPE:6446), the current EBITDA Margin % is 43.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaEssentia (TPE:6446) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaEssentia stock appears to be overvalued.
The current stock price of NT$1,445.00 is trading 7% above its estimated GF Value™ of NT$1,350.18.
GuruFocus considers PharmaEssentia to be Fairly Valued.
Key valuation signals for TPE:6446:
EBITDA Margin %: 43.50%
GF Value™: NT$1,350.18 vs. price of NT$1,445.00 (7% above fair value)
Industry Position: 247.6% above the Drug Manufacturers median (#92 of 956)
No single metric tells the full story. See the TPE:6446 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaEssentia Corp engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API and new drug patterns developments. Its products include BESREMi, Ropeginterferon alfa-2b, Ropeg + anti PD-1, PEG-IL-2, PEG-Cytokines, PD-1-IL-2v, NY-ESO-1 TCR-T, among others. It derives revenue from medicine products sales from contracts with customers.
82GF Score
Get the complete analysis for TPE:6446
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6446 has been successfully added to your 
